Anticoagulation After Gastrointestinal Bleeding

Hold the oral anticoagulant during active clinically significant GI bleeding, determine the last dose and agent, and pursue definitive hemostasis with endoscopic therapy or radiologic intervention when indicated. Acute endoscopic or radiologic intervention can be performed effectively in anticoagulated patients; the immediate objective is control of the GI source rather than waiting for complete drug clearance. BMJBMJEndoscopy in patients on antiplatelet or anticoagulant therapy - Gut

Document the lesion and adequacy of hemostasis before choosing a restart date. A treated focal lesion with sustained cessation of bleeding supports earlier re-exposure than an untreated, recurrent, malignant, variceal, or otherwise unresolved source. Prior GI bleeding is an important predictor of recurrent bleeding during DOAC treatment, so a prior event should trigger review of the source and modifiable coexposures rather than empiric permanent anticoagulant cessation. Oxford AcademicOxford AcademicRisk of gastrointestinal rebleeding in direct oral anticoagulant-treated population | Postgraduate Medical Journal | Oxford Academic

If warfarin excess requires reversal, recognize that vitamin K reduces subsequent responsiveness to warfarin and can leave the patient without therapeutic anticoagulation for a prolonged interval. When rapid anticoagulation is subsequently required, heparin may be preferable during re-establishment of anticoagulation, but this decision should be individualized to the thrombotic indication and post-hemostasis bleeding risk. accessdata fdaaccessdata fda[PDF] COUMADIN® TABLETS (Warfarin Sodium Tablets, USP) Crystalline ...

Observational studies and meta-analyses consistently find a net clinical benefit from restarting anticoagulation after GI bleeding: thromboembolism and death decrease, while recurrent bleeding risk increases. In atrial fibrillation, resumption of oral anticoagulation after a first GI bleed reduced thromboembolism but increased major bleeding without a statistically significant increase in recurrent GI bleeding in a Danish nationwide study. BMJ+3BMJEndoscopy in patients on antiplatelet or anticoagulant therapy - GutBMJTiming of anticoagulation restart after serious bleeding in atrial ...WileyRecurrent bleeding and thrombotic events after resumption of oral ...PubMedRisk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review

Treat thrombotic risk as highest when the anticoagulant indication remains compelling and interruption is likely to have immediate consequence. In atrial fibrillation, use CHA2DS2-VASc to structure embolic-risk assessment; in all patients, account for the indication, prior thromboembolism, and whether antiplatelet therapy is also necessary. High cardiovascular risk favors avoiding unnecessary delay once hemostasis is achieved. BMJBMJAsia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018 | Gut

Separate anticoagulant management from antiplatelet management. In patients taking aspirin for established cardiovascular disease who had actively bleeding peptic ulcers treated endoscopically, immediate aspirin resumption produced lower 8-week all-cause mortality than placebo (1.3% versus 12.9%), although 30-day rebleeding was numerically approximately twice as frequent. This result supports early review with cardiology when aspirin interruption is being considered, particularly when the cardiovascular indication is secondary prevention. BMJ+1BMJManagement of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines | GutBMJManagement of patients on antithrombotic agents

For warfarin, timing recommendations vary with thrombotic risk and the completeness of hemostasis. The APAGE-APSDE guideline recommends early resumption after day 3 for patients at high thromboembolic risk because early rebleeding decreases considerably after the first 3 days. The guideline also notes ESGE guidance that restarting warfarin between 7 and 15 days appears safe and effective for most patients. BMJ+1BMJManagement of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines | GutBMJManagement of patients on antithrombotic agents

For DOACs, restart after hemostasis can generally occur earlier than with warfarin because drug effect dissipates in approximately 1-2 days after stopping and returns within hours of re-dosing. For high cardiovascular-risk patients, one consensus recommends DOAC resumption within 1-2 days once bleeding is controlled, while recognizing that rapid restoration of anticoagulation can increase rebleeding risk. BMJBMJAsia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018 | Gut

Do not bridge a DOAC interruption with heparin solely to accelerate anticoagulant effect. DOACs have short half-lives and rapid onset, and guidelines state that bridging is unnecessary; perioperative evidence further associates bridging with increased bleeding without reduction in thromboembolism. BMJ+2BMJManagement of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines | GutPubMedPerioperative Anticoagulation Management - StatPearls - NCBI - NIHPubMedAnticoagulation Safety - StatPearls - NCBI Bookshelf - NIH

The evidence base for exact restart timing is limited and heterogeneous. In warfarin-treated patients after GI bleeding, restarting after 7 days rather than after 30 days was associated with lower death and thromboembolism without increased GI bleeding. Use this directional evidence to avoid prolonged interruption when hemostasis is secure, rather than treating day 7 as a universal threshold. BMJ+1BMJEndoscopy in patients on antiplatelet or anticoagulant therapy - GutBMJTiming of anticoagulation restart after serious bleeding in atrial fibrillation

Before restarting, reassess whether the original agent remains appropriate. In DOAC-eligible patients, agent selection should be matched to patient factors, including prior GI bleeding, chronic kidney disease, liver disease, older age, and concurrent antiplatelet therapy. Renal-function monitoring and evidence-based dose adjustment are specifically emphasized in chronic kidney disease. Wiley+1WileyPractical Recommendations for Anticoagulation in Patients With Atrial Fibrillation - Johner - 2026 - European Journal of Clinical Investigation - Wiley Online LibraryPubMedRisk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review

Identify co-medications that make recurrent bleeding more likely. Risk factors supporting proton-pump inhibitor use include a history of GI bleeding or peptic ulcer disease, Helicobacter pylori infection, cirrhosis, dyspepsia, advanced age, excessive alcohol use, antiplatelet treatment, NSAID use, and corticosteroid exposure. WileyWileyPractical Recommendations for Anticoagulation in Patients With Atrial Fibrillation - Johner - 2026 - European Journal of Clinical Investigation - Wiley Online Library

At the restart visit or discharge transition, document the intended agent, dose, first dose date, aspirin or P2Y12 plan, renal-function follow-up, and symptoms that require urgent reassessment. For warfarin, restart requires systematic INR testing, tracking, follow-up, and dose adjustment; vitamin K exposure may alter subsequent dose response. accessdata fda+1accessdata fda[PDF] COUMADIN® TABLETS (Warfarin Sodium Tablets, USP) Crystalline ...ScienceDirectGastrointestinal bleeding in patients receiving long-term anticoagulant therapy - ScienceDirect

Obtain multidisciplinary input when the patient has high cardiovascular risk, ongoing antiplatelet requirements, advanced kidney or liver disease, recurrent bleeding, or an uncertain GI source. A consensus approach recommends involving cardiology, gastroenterology, intensive care when relevant, and the patient after bleeding control; nephrology or hepatology input is appropriate when renal or hepatic dysfunction makes anticoagulant selection or dosing uncertain. BMJ+1BMJAsia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018 | GutPubMedAnticoagulation Safety - StatPearls - NCBI Bookshelf - NIH

For patients with both anticoagulant and antiplatelet indications, explicitly assign each drug an indication and a restart plan. Aspirin interruption after peptic-ulcer bleeding in secondary cardiovascular prevention can carry substantial mortality consequence, whereas combined antithrombotic treatment increases bleeding risk; this is a reason for coordinated risk adjudication, not a reason to restart all agents simultaneously without review. BMJ+2BMJManagement of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines | GutBMJManagement of patients on antithrombotic agentsBMJTiming of anticoagulation restart after serious bleeding in atrial ...

Escalate urgently for recurrent hemodynamic compromise, recurrent overt bleeding after restart, inability to secure endoscopic control, or a suspected non-GI bleeding syndrome. Anticoagulant-associated intracranial hemorrhage requires neurology and neurosurgical input for reversal, procedural decisions, and restart timing rather than use of the GI framework. PubMedPubMedAnticoagulation Safety - StatPearls - NCBI Bookshelf - NIH